Laura Brandt
Overview
Explore the profile of Laura Brandt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
440
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Balise R, Hu M, Calderon A, Odom G, Brandt L, Luo S, et al.
PLoS One
. 2024 Nov;
19(11):e0312695.
PMID: 39570967
Several large-scale, pragmatic clinical trials on opioid use disorder (OUD) have been completed in the National Drug Abuse Treatment Clinical Trials Network (CTN). However, the resulting data have not been...
2.
Empirically contrasting urine drug screening-based opioid use disorder treatment outcome definitions
Brandt L, Odom G, Hu M, Castro C, Balise R
Addiction
. 2024 Apr;
119(7):1289-1300.
PMID: 38616571
Background And Aims: A lack of consensus on the optimal outcome measures to assess opioid use disorder (OUD) treatment efficacy and their precise definition and computation has hampered the pooling...
3.
Kim Y, Brandt L, Cheung K, Nunes E, Roll J, Luo S, et al.
medRxiv
. 2024 Apr;
PMID: 38585900
Contingency Management (CM) is a psychological treatment that aims to change behavior with financial incentives. In substance use disorders (SUDs), deployment of CM has been enriched by longstanding discussions around...
4.
Luo S, Feaster D, Liu Y, Balise R, Hu M, Bouzoubaa L, et al.
JAMA Psychiatry
. 2023 Oct;
81(1):45-56.
PMID: 37792357
Importance: No existing model allows clinicians to predict whether patients might return to opioid use in the early stages of treatment for opioid use disorder. Objective: To develop an individual-level...
5.
OBryan G, Ensminger A, Billah I, Sithole E, Nghatanga M, Brandt L, et al.
BMC Health Serv Res
. 2023 Sep;
23(1):1044.
PMID: 37773121
Background: Surgical voluntary medical male circumcision (VMMC) is a safe procedure; however, maintaining quality standards at scale, particularly during scale-up, is a challenge making ongoing quality management (QM) efforts essential....
6.
Odom G, Brandt L, Castro C, Luo S, Feaster D, Balise R
PLoS One
. 2023 Sep;
18(9):e0291248.
PMID: 37682922
Introduction: The efficacy of treatments for substance use disorders (SUD) is tested in clinical trials in which participants typically provide urine samples to detect whether the person has used certain...
7.
Brandt L, Hu M, Nunes E, Campbell A
Drug Alcohol Depend
. 2023 May;
248:109918.
PMID: 37224673
Background: The selection of appropriate efficacy endpoints in clinical trials has been a long-standing challenge for the substance use disorder field. Using data from a large, multi-site National Drug Abuse...
8.
Brandt L, Hu M, Liu Y, Castillo F, Odom G, Balise R, et al.
Am J Psychiatry
. 2023 Mar;
180(5):386-394.
PMID: 36891640
Objective: Overdose risk during a course of treatment with medication for opioid use disorder (MOUD) has not been clearly delineated. The authors sought to address this gap by leveraging a...
9.
Pan Y, Feaster D, Odom G, Brandt L, Hu M, Weiss R, et al.
Drug Alcohol Depend Rep
. 2023 Jan;
5.
PMID: 36644227
Introduction: While polysubstance use has consistently been associated with higher rates of relapse, few studies have examined subgroups with specific combinations and time course of polysubstance use (i.e., polysubstance use...
10.
Martinez S, Brandt L, Comer S, Levin F, Jones J
Addict Neurosci
. 2022 Sep;
4.
PMID: 36120106
Aims: Consistent with the opponent process theory individuals with chronic opioid use should predominantly endorse the avoidance of aversive negative emotional and/or physiological states as the motivation for continued opioid...